TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03460990
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received TEZ/IVA orally once daily in the morning.
Study: NCT03460990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Study: NCT03460990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
Study: NCT00458445
Drug: SPD465
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00374049
Drug: MUC_1
Normalized name: Mucin-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
Study: NCT01958060
Drug: Placebo to BI 1034020
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous part
Study: NCT01120899
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take 100 mg minocycline pills twice daily for 24 months.
Study: NCT01602874
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
Study: NCT01602874
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study: NCT01602874
Drug: CAP: Ceftriaxone, plus if applicable oral clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study: NCT03510884
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT03510884
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03510884
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03510884
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03510884
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT03510884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous injection
Study: NCT00428818
Drug: trimethoprim-sulfamethoxazole or doxycycline
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03436953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01134198
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02111434
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Study: NCT00658957
Drug: gentamicin-collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 cm sponge
Study: NCT00658957
Drug: placebo collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 cm sponge
Study: NCT03966950
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
Study: NCT04472858
Drug: CS1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
Study: NCT01636817
Drug: NNC0109-0012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Study: NCT01636817
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Study: NCT03003364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a blinded syringe
Study: NCT03244605
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
Study: NCT03244605
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
Study: NCT01863186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
Study: NCT01427881
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04383717
Drug: Levamisole and isoprinosine
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
Study: NCT04383717
Drug: Azithromycin and hydroxychloroquine
Normalized name: cefixime and azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
Study: NCT01151449
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00004424
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00925873
Drug: Experimental (fludarabine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2.
Study: NCT01909739
Drug: atrovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Study: NCT01909739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Study: NCT03225352
Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intake of 1 tablet, 500mg
Study: NCT03225352
Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intake of 1 tablet, 1000mg
Study: NCT03225352
Drug: 400 mg ibuprofen(Nurofen)
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single intake of 1 tablet, 400mg
Study: NCT03225352
Drug: 400 mg ibuprofen (Dolormin Extra)
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single intake of 1 tablet, 400mg
Study: NCT00089427
Drug: IL13-PE38QQR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01740791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT02686762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
Study: NCT00650273
Drug: Azithromycin Tablets 600 mg
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, single dose fasting
Study: NCT00650273
Drug: Zithromax® Tablets 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, single dose fasting
Study: NCT02690935
Drug: 2LALERG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic drug
Study: NCT02690935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02123524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00800618
Drug: PF-02413873 100 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of PF-02413873 oral suspension once daily for 14 days
Study: NCT00800618
Drug: PF-02413873 500 mg QD
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg of PF-02413873 oral suspension once daily for 14 days
Study: NCT00800618
Drug: PF-02413873 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-0241383 Placebo once daily for 14 days
Study: NCT06048887
Drug: CRN04894 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Study: NCT06048887
Drug: Placebo Oral Solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03187587
Drug: Standard chemotherapy treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard chemotherapy treamtment arm recieves only chemotherapy.
Study: NCT02997722
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 100 ml of normal saline over 45 minutes.
Study: NCT00032916
Drug: NS2359
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000425
Drug: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000425
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00176930
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
Study: NCT02674386
Drug: Investigational Medical Product (IMP) administered in parent study
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
Study: NCT00476593
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
Study: NCT00004188
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004188
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03171623
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administration, single dose
Study: NCT00807209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
Study: NCT00807209
Drug: Fentanyl via PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl via PCA
Study: NCT01040793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Study: NCT02094261
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet 80 mg
Study: NCT00337987
Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
Study: NCT00373425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00351286
Drug: Background simvastatin at a stable dose of 40 mg qHS
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00311220
Drug: tuberculin for skin test
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01242644
Drug: ropivacaine, ketorolac , morphine sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
Study: NCT01666977
Drug: AMG 386 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 Placebo
Study: NCT01097551
Drug: Iontophoresis with acetylcholine delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with acetylcholine delivery
Study: NCT02093923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo subcutaneously.
Study: NCT01195116
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mcg/kg/hr
Study: NCT04640012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally administered
Study: NCT01065116
Drug: AL Blister-packs with Instruction leaflets
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL Blister packs with instruction leaflets will be dispensed
Study: NCT00277043
Drug: taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
Study: NCT00825864
Drug: diclofenac drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop 4 times a day for 3 months
Study: NCT00500318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose matched placebo, once daily oral inhalation.
Study: NCT00223938
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iron
Study: NCT00945334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 14 days tid
Study: NCT00458107
Drug: SCA-136
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01813435
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
Study: NCT01497119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=tablet, route=oral use, once daily for 6 weeks.
Study: NCT02332005
Drug: diepalrestat choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: aldose reductase inhibitor
Study: NCT03429049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving Placebo injection
Study: NCT02656251
Drug: 0.12% Clorhexidine with alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
Study: NCT02656251
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo every 12 hours for 04 days
Study: NCT02656251
Drug: 0.12% Clorhexidine without alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
Study: NCT00996424
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation with normal saline solution
Study: NCT04478708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
Study: NCT02992457
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: three months in repeated treatment failure
Study: NCT04459676
Drug: Standard of Care (SOC) + ANG-3777
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) + ANG-3777
Study: NCT04459676
Drug: Standard Of Care (SOC) + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Of Care + Placebo
Study: NCT00099580
Drug: AC2592
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous subcutaneous infusion (via pump), dose based on subject body weight
Study: NCT00804245
Drug: PET-CT scans supplemented with 11C-Choline tracer
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
Study: NCT00108667
Drug: IV Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03963362
Drug: GLA5PR tablet 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLARS-NF3 tablet
Study: NCT03963362
Drug: GLA5PR tablet 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLARS-NF3 tablet
Study: NCT00631007
Drug: INT131 besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, oral
Study: NCT00631007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, oral
Study: NCT01231373
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of vehicle comparator
Study: NCT02328755
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
Study: NCT00263887
Drug: Albumin (Human) 20%, United States Pharmacopeia (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
Study: NCT03211455
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous isotonic saline
Study: NCT04053673
Drug: RBN-2397
Approvals — FDA: no, EMA: no, PMDA: no
Description: an oral PARP7 Inhibitor
Study: NCT03129776
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
Study: NCT02913131
Drug: Pyruvate (13C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyruvate injection followed by an MRI scan.
Study: NCT04481750
Drug: MT-1186-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution or suspension
Study: NCT03263442
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg IV three times daily for seven days
Study: NCT03263442
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV three times daily for seven days